Gilde Healthcare Cooperatieve Sells 47,686 Shares of LAVA Therapeutics (NASDAQ:LVTX) Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 47,686 shares of LAVA Therapeutics stock in a transaction on Monday, October 13th. The shares were sold at an average price of $1.54, for a total transaction of $73,436.44. Following the completion of the sale, the insider directly owned 5,246,492 shares in the company, valued at $8,079,597.68. This represents a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Tuesday, October 14th, Gilde Healthcare Cooperatieve sold 227,341 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.51, for a total transaction of $343,284.91.
• On Friday, October 10th, Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.55, for a total transaction of $77,296.95.
• On Thursday, October 9th, Gilde Healthcare Cooperatieve sold 48,169 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.56, for a total transaction of $75,143.64.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.57, for a total transaction of $45,457.78.

LAVA Therapeutics Trading Up 0.3%

LVTX stock opened at $1.52 on Friday. LAVA Therapeutics N.V. has a 12-month low of $0.85 and a 12-month high of $2.09. The business’s 50-day moving average is $1.55 and its 200 day moving average is $1.39. The stock has a market cap of $39.99 million, a price-to-earnings ratio of -1.45 and a beta of 0.50.

LAVA Therapeutics (NASDAQ:LVTX) last released its earnings results on Wednesday, August 13th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). As a group, equities analysts forecast that LAVA Therapeutics N.V. will post -1.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LVTX shares. HC Wainwright decreased their price objective on LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating on the stock in a report on Tuesday, August 5th. Jefferies Financial Group downgraded shares of LAVA Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $3.00 to $1.50 in a research note on Tuesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LAVA Therapeutics in a research report on Wednesday, October 8th. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $2.69.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LVTX. BML Capital Management LLC acquired a new position in LAVA Therapeutics in the 1st quarter valued at about $2,490,000. Rangeley Capital LLC purchased a new stake in shares of LAVA Therapeutics during the 2nd quarter valued at approximately $36,000. XTX Topco Ltd acquired a new position in LAVA Therapeutics in the first quarter valued at approximately $31,000. Finally, Lepercq De Neuflize Asset Management LLC acquired a new position in LAVA Therapeutics in the first quarter valued at approximately $29,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.